Proficio Capital Partners LLC Purchases Shares of 25,770 Simulations Plus, Inc. (NASDAQ:SLP)

Proficio Capital Partners LLC acquired a new stake in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,770 shares of the technology company's stock, valued at approximately $719,000. Proficio Capital Partners LLC owned about 0.13% of Simulations Plus at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Conestoga Capital Advisors LLC raised its position in shares of Simulations Plus by 15.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company's stock valued at $62,090,000 after purchasing an additional 290,414 shares during the period. Tributary Capital Management LLC raised its holdings in Simulations Plus by 21.7% during the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company's stock valued at $11,047,000 after acquiring an additional 70,526 shares during the period. Stephens Inc. AR purchased a new stake in shares of Simulations Plus during the fourth quarter worth $905,000. BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company's stock worth $1,279,000 after acquiring an additional 32,002 shares during the period. Finally, State Street Corp raised its stake in shares of Simulations Plus by 4.7% during the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company's stock valued at $20,503,000 after purchasing an additional 28,953 shares during the period. 78.08% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several research analysts have commented on SLP shares. William Blair restated an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp upped their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Simulations Plus Stock Performance

SLP traded down $0.72 on Wednesday, reaching $24.00. The company had a trading volume of 186,248 shares, compared to its average volume of 166,980. Simulations Plus, Inc. has a 52-week low of $23.73 and a 52-week high of $51.22. The company has a market cap of $482.21 million, a price-to-earnings ratio of 60.00 and a beta of 0.89. The business has a 50 day simple moving average of $31.15 and a 200 day simple moving average of $30.72.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares of the company's stock, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 19.40% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.